학술자료
Academic Material
[Lactobacillus casei] Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial
- e 2077
Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial
Beitullah ALIPOUR, 1 Aziz HOMAYOUNI-RAD, 2 Elnaz VAGHEF-MEHRABANY, 3 Sakineh Khatoun SHARIF, 4 Leila VAGHEF-MEHRABANY, 5 Mohammad ASGHARI-JAFARABADI, 6Mohammad Reza NAKHJAVANI, 4 and Javad MOHTADI-NIA 21 Department of Community Nutrition, Tabriz University of Medical Sciences, Tabriz, 2 Department of Food Science and Technology, Tabriz University of Medical Sciences, Tabriz, 3 Department of Nutrition, Biochemistry and Diet Therapy, Faculty of Nutrition,Tabriz University of Medical Sciences, Tabriz, 4 Department of Rheumatology, Faculty of Medicine, Tabriz University of Medical Sciences, 5 Department of Nutrition, Faculty of Nutrition and Diet Therapy, Tehran University of Medical Sciences, Tehran, and 6 Traffic Injury Prevention Research Center, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
The present study aimed at investigating the effects of Lactobacillus casei 01 supplementation on symptoms and inflammatory biomarkers of rheumatoid arthritis (RA) in women.
In this randomized double-blind clinical trial, female patients with established RA for more than 1 year, 20–80 years of age and body mass index (BMI) lower than 40, who followed stable medication for 3 months prior to the supplementation, were randomly allocated to receive either one capsule containing 10 8 colony forming units (CFU) of L. casei 01, or a placebo for 8 weeks; allocation was stratified by BMI and menopausal status. Disease activity score-28 (DAS28) was calculated, European League Against Rheumatism (EULAR) response was evaluated and the cytokines, interleukin (IL)-1b, IL-6, IL-10, IL-12 and tumor necrosis factor (TNF)-a were measured.
Thirty patients were recruited in each group; 22 and 24 patients were analyzed in the probiotic and placebo groups, respectively. L. casei 01 supplementation decreased serum high-sensitivity C-reactive protein (hs-CRP) levels, tender and swollen joint counts, global health (GH) score and DAS28 (P < 0.05). More patients in the L. casei 01 group had moderate response to the treatment, based on the EULAR criteria, at the end of the study (P < 0.01). At the end of the study, a significant difference was observed between the two groups for IL-10, IL-12 and TNF-a changes through the study course (P < 0.05), in favor of the probiotic group. No adverse effects were reported for the intervention.
Probiotic supplementation may be an appropriate adjunct therapy for RA patients and help alleviate symptoms and improve inflammatory cytokines.
DAS28, EULAR criteria, inflammatory cytokines, probiotics, rheumatoid arthritis. |
제목
Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial
목표
본 연구는 여성에서 류마티스 관절염 (RA)의 증상 및 염증 생체표지자에 대한 Lactobacillus casei 01 보충제의 효과를 조사하는 것을 목표로 하였다.
방법
이 무작위 이중맹검 임상 시험에서 1년 동안, 20-80세 및 BMI가 40 미만인 RA 환자 중 3개월 이상 안정적인 약물을 복용 한 여성 환자들을 대상으로 L.casei 01의 108 CFU를 포함하는 하나의 캡슐 또는 8주 동안의 위약을 받는 환자들을 무작위로 할당하였다; 할당은 BMI와 폐경 상태에 의해 층화되었다. IL-1β, IL-6, IL-10, IL-12 및 종양괴사인자(TNF)에 대한 유럽 연합의 류마티스반응(EULAR)-α으로 측정되었다.
결과
각 그룹에는 30명의 환자가 모집되었다. 22명의 환자와 24명의 환자를 각각 probiotic 군과 위약군으로 분석 하였다. L.casei 01 보충군은 혈청 고감도 C-반응성 단백(hs-CRP)수치, 부드럽고 부어 오른 관절 수, 전반적인 건강(GH) 점수 및 DAS28(P<0.05)을 감소시켰다. L. casei 01 그룹의 더 많은 환자는 연구가 끝날 때 EULAR 기준에 따라 치료에 대해 중간 정도의 반응을 보였다(P<0.01). 연구 종료 시 연구 과정을 통해 IL-10, IL-12 및 TNF-α 변화에 대해 두 그룹간의 유의한 차이가 관찰되었으며 (P<0.05), 프로바이오틱 그룹에 유리하게 작용했다. 개입에 대한 부작용은 보고되지 않았다.
결론
Probiotic의 보충은 RA 환자를 위한 적절한 보조 치료 일 수 있으며 증상 완화 및 염증성 사이토카인 개선에 도움이 된다.
[출처 : 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd]
| no. | 제목 | 조회수 |
|---|
| 20 |  | 2081 | |
| 19 |  | [Gut Microbiome] Acetate mediates a microbiome–brain–β cell axis to promote metabolic syndrome | 2202 |
| 18 |  | 2031 | |
| 17 |  | [Gut Microbiome] The Gut Microbiome in Human Neurological Disease: A Review | 2534 |
| 16 |  | [Gut Microbiome] Rapidly expanding knowledge on the role of the gut microbiome in health and disease | 2180 |
| 15 |  | 2222 | |
| 14 | | 2414 | |
| 13 | | 2359 | |
| 12 | | 2441 | |
| 11 | | 2459 | |
| 10 | | [Bacillus] Anti-influenza Activity of a Bacillus subtilis Probiotic Strain | 2119 |
| 9 | | [Bacillus] Aflatoxin B1 degradation by Bacillus subtilis UTBSP1 isolated from pistachio nuts of Iran | 2272 |
| 8 | | 2349 | |
| 7 | | 3238 | |
| 6 | | 2124 | |
| 5 | | 2339 | |
| 4 | | 2297 | |
| 3 | | 2111 | |
| 2 | | 2077 | |
| 1 | | 2402 |
㈜마이크로바이옴 ㅣ 서울시 서대문구 연희로 77-12 영화빌딩2층
Tel :02-322-0302 l Fax : 02-322-0759
Copyright (c) Microbiome. Co. All Rights Reserved.